Ferroptosis Findings

Emerging evidence that berberine can promote ferroptosis in selected cancer models

Why ferroptosis matters

Ferroptosis is an iron-dependent regulated cell-death pathway driven by lipid peroxidation.

It is distinct from apoptosis, autophagy, and necroptosis.

This matters because some cancers that resist apoptosis may still remain vulnerable to ferroptosis.

The core ferroptosis axis

Ferroptosis is restrained by a defence system built around:

SLC7A11 / System Xc- for cystine import
glutathione (GSH) synthesis
GPX4 to neutralise lipid peroxides
upstream Nrf2 signalling

If that defence collapses, lipid peroxides accumulate and the cell can undergo ferroptotic death.

How berberine may induce ferroptosis

Berberine appears to hit this system at more than one point.

Reported mechanisms include:

downregulation of SLC7A11
depletion of intracellular GSH
suppression of GPX4
indirect weakening of the pathway through Nrf2 suppression

That combination can make tumour cells less able to buffer lipid oxidative damage.

Cancer models of interest

Preclinical ferroptosis findings have been reported in:

oral cancer models
non-small-cell lung cancer models
triple-negative breast-cancer models

The NSCLC work is especially interesting because berberine has also been studied in combination with ferroptosis-inducing strategies.

Why this matters in resistant disease

Many aggressive tumours evade treatment by blocking apoptosis.

Ferroptosis bypasses that route.

That makes berberine's ferroptosis signal especially relevant in resistant disease settings such as TNBC, NSCLC, and other high-stress tumours.

Important context

Berberine's ferroptosis effect appears context-dependent.

In non-cancer tissue, berberine has also shown the opposite pattern in some models, helping protect cells through Nrf2-linked antioxidant signalling.

That fits the broader pattern of tumour selectivity rather than a simple one-direction effect.

Practical interpretation

Berberine may matter here not because it is a pure ferroptosis drug, but because it weakens several ferroptosis-defence systems at once.

That gives it potential value in apoptosis-resistant cancers and in combination strategies designed to increase oxidative pressure.

The evidence is still preclinical.

Where to Go Next

Key References

Berberine as a Potential Anticancer Agent: A Comprehensive Review
PMC Full Text: PMC8658774

Islam MN et al. (2021). Molecules, 26(23):7368. PMC8658774

Sajeev A et al. (2024). Cancer Letters, 597:217019. doi.org/10.1016/j.canlet.2024.217019

Feng X et al. (2022). Evid Based Complement Alternat Med, 2022:1189034. PMC9316001

Evidence-Based Complementary and Alternative Medicine (Hindawi/Wiley) — Open Access
PMC Full Text: PMC9316001

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.